Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ikit s.r.l via degli olmetti 46 00060 formello (rm) taliansko -

Unione Europea - slovacco - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - chrípka, človek - vakcíny - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Unione Europea - slovacco - EMA (European Medicines Agency)

dompé biotec s.p.a. - darbepoetínu alfa - kidney failure, chronic; anemia; cancer - antianemické prípravky - liečba symptomatickej anémie spojenej s chronickým zlyhaním obličiek (crf) u dospelých a detských pacientov. liečbu symptomatických anémia u dospelých pacientov s rakovinou s non-myeloidná malignancies dostávajú chemoterapiu.

Unione Europea - slovacco - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanóm - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Unione Europea - slovacco - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - svrab - imunosupresíva - treatment of moderate-to-severe plaque psoriasis in adults.

Unione Europea - slovacco - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastické činidlá - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Unione Europea - slovacco - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastické činidlá - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Slovacchia - slovacco - myHealthbox

bayer ag - olejová disperzia - foramsulfuron 50 g/l; thiencarbazone-methyl 30 g/l

Slovacchia - slovacco - myHealthbox

bayer ag - olejová disperzia - foramsulfuron 50 g/l; thiencarbazone-methyl 30 g/l

Unione Europea - slovacco - EMA (European Medicines Agency)

sanofi b.v. - laronidáza - mucopolysacharidóza i - iné alimentárny trakt a metabolizmus výrobky, - aldurazyme je určený pre dlhodobé enzým substitučná terapia u pacientov s potvrdená diagnóza mucopolysaccharidosis i (mps i, alfa-l-iduronidase nedostatok) na liečbu nonneurological prejavy ochorenia.